ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 102 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,350,035 | -23.6% | 719,014 | -2.0% | 0.00% | – |
| Q2 2023 | $5,692,829 | +807.3% | 733,612 | +566.4% | 0.00% | – |
| Q1 2023 | $627,456 | -51.6% | 110,080 | -50.0% | 0.00% | – |
| Q4 2022 | $1,296,742 | +268.4% | 220,160 | +100.0% | 0.00% | – |
| Q3 2022 | $352,000 | -28.6% | 110,080 | 0.0% | 0.00% | – |
| Q2 2022 | $493,000 | -84.4% | 110,080 | -81.5% | 0.00% | – |
| Q1 2022 | $3,170,000 | -83.0% | 593,549 | -53.3% | 0.00% | -100.0% |
| Q4 2021 | $18,696,000 | -15.6% | 1,271,828 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $22,162,000 | +0.1% | 1,059,899 | -15.3% | 0.00% | 0.0% |
| Q2 2021 | $22,146,000 | -33.8% | 1,251,913 | -8.3% | 0.00% | -50.0% |
| Q1 2021 | $33,456,000 | +175.3% | 1,365,565 | +280.3% | 0.00% | +100.0% |
| Q4 2020 | $12,154,000 | +303.9% | 359,043 | +198.4% | 0.00% | – |
| Q3 2020 | $3,009,000 | -9.0% | 120,320 | +22.8% | 0.00% | – |
| Q2 2020 | $3,305,000 | – | 97,991 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |